[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334957-105":59,"doc-detail-334957-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","ib-kinase-inhibitor-bay-11-7082-promotes-anti-tumor-effect-in-ras-driven-cancers","IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers","","Oncogenic RAS mutations drive uncontrolled cell growth and tumorigenesis, while effective targeting of RAS-mutant cancers remains difficult. This study evaluates BAY 11-7082, an IκBα kinase inhibitor, across multiple RAS-mutant models. Cell viability assays and subcutaneous xenografts confirm growth inhibition. Large RNA sequencing maps differential gene and pathway regulation, revealing PI3K-AKT pathway suppression and apoptosis activation, with pathway effects varying by RAS subtype.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ib-kinase-inhibitor-bay-11-7082-promotes-anti-tumor-effect-in-ras-driven-cancers/334957/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ib-kinase-inhibitor-bay-11-7082-promotes-anti-tumor-effect-in-ras-driven-cancers/334957.png","ImageObject",300,407,{"name":92,"@type":93},"Maeve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main therapeutic goal addressed in this study?","Question",{"text":112,"@type":113},"To inhibit cancer growth in RAS-mutant tumors by targeting IκBα kinase with BAY 11-7082.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the researchers test BAY 11-7082’s effects?",{"text":117,"@type":113},"They used cell culture viability assays and in vivo subcutaneous xenograft assays, supported by large RNA sequencing to identify regulated genes and pathways.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanistic pathway changes were observed after BAY 11-7082 treatment?",{"text":121,"@type":113},"BAY 11-7082 suppressed the PI3K-AKT signaling pathway and activated apoptosis across RAS mutant cell lines.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334957,1790843542,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":14,"preview_urls":146},5909877438554,"https://ap-avatar.wpscdn.com/avatar/5600025385ad2bf12a7?_k=1778553567797529272","Guruvaiah and Gupta Journal of Translational Medicine (2024) 22:642  \n[https://doi.org/10.1186/s12967-024-05384-4](https://doi.org/10.1186/s12967-024-05384-4)  \nJournal of Translational Medicine  \nRESEARCH Open Access  \nIκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers  \nPraveen Guruvaiah 1 and Romi Gupta 1,2*  \nAbstract  \nBackground Oncogenic mutations in the RAS gene are associated with uncontrolled cell growth, a hallmark feature contributing to tumorigenesis. While diverse therapeutic strategies have been diligently applied to treat RAS-mutant cancers, successful targeting of the RAS gene remains a persistent challenge in the field of cancer therapy. In our study, we discover a promising avenue for addressing this challenge.  \nMethods In this study, we tested the viability of several cell lines carrying oncogenic NRAS, KRAS, and HRAS mutations upon treatment with IkappaBalpha (IκBα) inhibitor BAY 11-7082 . We performed both cell culture-based viability assay and in vivo subcutaneous xenograft-based assay to confirm the growth inhibitory effect of BAY 11-7082. We also performed large RNA sequencing analysis to identify differential ly regulated genes and pathways in the context of oncogenic NRAS, KRAS, and HRAS mutations upon treatment with BAY 11-7082.  \nResults We demonstrate that oncogenic NRAS, KRAS, and HRAS activate the expression of IκBα kinase. BAY 11-7082, an inhibitor of IκBα kinase, attenuates the growth of NRAS, KRAS, and HRAS mutant cancer cells in cell culture and in mouse model. Mechanistically, BAY 11-7082 inhibitor treatment leads to suppression of the PI3K-AKT signaling pathway and activation of apoptosis in all RAS mutant cell lines. Additionally, we find that BAY 11-7082 treatment results in the downregulation of different biological pathways depending upon the type of RAS protein that may also contribute to tumor growth inhibition.  \nConclusion Our study identifies BAY 11-7082 to be an efficacious inhibitor for treating RAS oncogene (HRAS, KRAS, and NRAS) mutant cancer cells. This finding provides new therapeutic opportunity for effective treatment of RASmutant cancers.  \nKeywords NRAS, KRAS, HRAS, MAPK, PI3K-AKT  \n*Correspondence: Romi Gupta [romigup@uab.edu](romigup@uab.edu)  \n1Department of Biochemistry and Molecular Genetics, The University of Alabama at Birmingham, Birmingham, AL 35233, USA  \n2O’Neal Comprehensive Cancer Center, The University of Alabama at Birmingham, Birmingham, AL 35233, USA  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ([http://creativecommons.org/publicdomain/zero/1.0/](http://creativecommons.org/publicdomain/zero/1.0/)) applies to the data made available in this article, unless otherwise stated in a credit line to the data.  \nGuruvaiah and Gupta Journal of Translational Medicine (2024) 22:642 Page 2 of 14  \nIntroduction  \nThe Rat sarcoma (RAS) family consists of several genes that encode proteins involved cell signaling pathways and key cellular processes such as cell proliferation, differentiation, and survival [1]. The three main RAS genes that ","cbCaic3L3Mq0Y89W","https://ap.wps.com/l/cbCaic3L3Mq0Y89W","pdf",13435506,14,"English","# Abstract\n# Introduction\n## RAS family and oncogenic signaling\n## KRAS mutation prevalence and therapeutic relevance\n## NRAS mutation biology and targeting strategies\n## HRAS mutations (section continues)","[{\"question\":\"What is the main therapeutic goal addressed in this study?\",\"answer\":\"To inhibit cancer growth in RAS-mutant tumors by targeting IκBα kinase with BAY 11-7082.\"},{\"question\":\"How did the researchers test BAY 11-7082’s effects?\",\"answer\":\"They used cell culture viability assays and in vivo subcutaneous xenograft assays, supported by large RNA sequencing to identify regulated genes and pathways.\"},{\"question\":\"What mechanistic pathway changes were observed after BAY 11-7082 treatment?\",\"answer\":\"BAY 11-7082 suppressed the PI3K-AKT signaling pathway and activated apoptosis across RAS mutant cell lines.\"}]","IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers | PDF",1790009030,35,[147,151],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/fdd0809b682cf78b46bd867e3c027530.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/6bfe430ddc247ae59c2bb18e5f4d4199.webp",982,1309]